Inimmune, a Missoula-based biotech company founded by nationally recognized vaccine scientists that has been working on a vaccine for COVID-19, announced today that it has raised $22 million in Series A funding led by Two Bear Capital, a venture-capital firm founded by Whitefish philanthropist Mike Goguen.
The firm plans to use the Series A investment to advance at least two late-stage pre-clinical drug candidates in oncology and allergy through Phase I human clinical trials.
The $22 million is believed to be largest round of Series A funding in state history, according to Two Bear Capital Chief Marketing Officer Liz Marchi, who has been involved in equity capital in Montana for decades.
READ FULL ARTICLE
